PCMA Backs Bipartisan Push to Eliminate Biosimilar Red Tape

PCMA backs bipartisan push to eliminate biosimilar red tape

WASHINGTON — The Pharmaceutical Care Management Association (PCMA) has stated strong support for the newly reintroduced Biosimilar Red Tape Elimination Act, bipartisan legislation aimed at streamlining market access for biosimilars and lowering prescription drug costs for consumers.Introduced by Senators Mike Lee (R-UT) and Ben Ray Luján (D-NM), the bill proposes to automatically deem biosimilars interchangeable with their brand-name biologic co…

PCMA Statement on Biosimilar Red Tape Elimination Act

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the introduction of the Biosimilar Red Tape Elimination Act: “We applaud Senators Mike Lee (R-UT) and Ben Ray Luján (D-NM) for re-introducing the Biosimilar Red Tape Elimination Act to increase competition within the biosimilar market and improve access to more affordable alternatives to brand name prescription drugs. “Increased competiti…